170 related articles for article (PubMed ID: 12586299)
1. Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model.
Le Guerhier F; Thermet A; Guerret S; Chevallier M; Jamard C; Gibbs CS; Trépo C; Cova L; Zoulim F
J Hepatol; 2003 Mar; 38(3):328-34. PubMed ID: 12586299
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection.
Thermet A; Buronfosse T; Werle-Lapostolle B; Chevallier M; Pradat P; Trepo C; Zoulim F; Cova L
J Gen Virol; 2008 May; 89(Pt 5):1192-1201. PubMed ID: 18420797
[TBL] [Abstract][Full Text] [Related]
3. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
4. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein.
Rollier C; Sunyach C; Barraud L; Madani N; Jamard C; Trepo C; Cova L
Gastroenterology; 1999 Mar; 116(3):658-65. PubMed ID: 10029625
[TBL] [Abstract][Full Text] [Related]
5. Progress in DNA vaccine for prophylaxis and therapy of hepatitis B.
Thermet A; Rollier C; Zoulim F; Trepo C; Cova L
Vaccine; 2003 Jan; 21(7-8):659-62. PubMed ID: 12531335
[TBL] [Abstract][Full Text] [Related]
6. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.
Delmas J; Schorr O; Jamard C; Gibbs C; Trépo C; Hantz O; Zoulim F
Antimicrob Agents Chemother; 2002 Feb; 46(2):425-33. PubMed ID: 11796353
[TBL] [Abstract][Full Text] [Related]
8. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.
Foster WK; Miller DS; Marion PL; Colonno RJ; Kotlarski I; Jilbert AR
Antimicrob Agents Chemother; 2003 Aug; 47(8):2624-35. PubMed ID: 12878529
[TBL] [Abstract][Full Text] [Related]
9. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo.
Nicoll A; Locarnini S; Chou ST; Smallwood R; Angus P
J Gastroenterol Hepatol; 2000 Mar; 15(3):304-10. PubMed ID: 10764033
[TBL] [Abstract][Full Text] [Related]
10. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
11. Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks.
Quinet J; Jamard C; Burtin M; Lemasson M; Guerret S; Sureau C; Vaillant A; Cova L
Hepatology; 2018 Jun; 67(6):2127-2140. PubMed ID: 29251788
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection.
Heijtink RA; De Wilde GA; Kruining J; Berk L; Balzarini J; De Clercq E; Holy A; Schalm SW
Antiviral Res; 1993 Jun; 21(2):141-53. PubMed ID: 8338351
[TBL] [Abstract][Full Text] [Related]
13. IFN-gamma increases efficiency of DNA vaccine in protecting ducks against infection.
Long JE; Huang LN; Qin ZQ; Wang WY; Qu D
World J Gastroenterol; 2005 Aug; 11(32):4967-73. PubMed ID: 16124047
[TBL] [Abstract][Full Text] [Related]
14. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.
Seignères B; Martin P; Werle B; Schorr O; Jamard C; Rimsky L; Trépo C; Zoulim F
Antimicrob Agents Chemother; 2003 Jun; 47(6):1842-52. PubMed ID: 12760857
[TBL] [Abstract][Full Text] [Related]
15. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines.
Feng F; Teoh CQ; Qiao Q; Boyle D; Jilbert AR
Vaccine; 2010 Oct; 28(46):7436-43. PubMed ID: 20833122
[TBL] [Abstract][Full Text] [Related]
16. [Experimental study on the effect of combination therapy with lamivudine and famciclovir against duck hepatitis B virus in vivo].
Chen Y; Guo S; Qi Z; Huang A
Zhonghua Gan Zang Bing Za Zhi; 2001 Aug; 9(4):209-11. PubMed ID: 11602049
[TBL] [Abstract][Full Text] [Related]
17. Antisense therapy of hepatitis B virus infection.
Offensperger WB; Offensperger S; Blum HE
Mol Biotechnol; 1998 Apr; 9(2):161-70. PubMed ID: 9658393
[TBL] [Abstract][Full Text] [Related]
18. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.
Tsiquaye KN; Slomka MJ; Maung M
J Med Virol; 1994 Mar; 42(3):306-10. PubMed ID: 8006644
[TBL] [Abstract][Full Text] [Related]
19. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.
Zoulim F; Berthillon P; Guerhier FL; Seigneres B; Germon S; Pichoud C; Cheng YC; Trepo C
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S460-3. PubMed ID: 12534778
[TBL] [Abstract][Full Text] [Related]
20. In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes.
Saade F; Buronfosse T; Guerret S; Pradat P; Chevallier M; Zoulim F; Jamard C; Cova L
J Viral Hepat; 2013 Apr; 20(4):e56-65. PubMed ID: 23490390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
